Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.
Fiche publication
Date publication
janvier 2019
Journal
Journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Cobo-Calvo A, Sepúlveda M, 'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R, ,
Lien Pubmed
Résumé
To analyze whether myelin oligodendrocyte glycoprotein antibody (MOG-Ab) titres at onset of the disease were different according to the clinical phenotype at presentation, and to investigate whether the titres were associated with risk of further relapses or predicted clinical outcome in adult patients. Finally, we assessed an alternative method to the classical measurement of MOG-Ab levels by serial dilutions.
Mots clés
MOG antibodies, Myelitis, Neuromyelitis optica, Optic neuritis, Prognosis, Titre
Référence
J. Neurol.. 2019 Jan 3;: